{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(17)"],"submitter":["Mahmood U"],"pubmed_abstract":["<h4>Purpose</h4>Evaluation of predictors and outcomes in NSCLC patients treated with an immune checkpoint inhibitor (ICI) following a severe immune-related adverse event (irAE).<h4>Methods</h4>We included all NSCLC patients receiving ≥1 ICI cycle and corticosteroids for CTCAE Grade ≥3 irAEs between 2017 and 2023 from three UK NHS teaching hospitals. Progression-free survival (PFS) and overall survival (OS) after the 1st irAE, best overall response (BOR) to ICI, and predictors of clinical benefit were evaluated. Kaplan-Meier, Cox and logistic regression models, and Wilcoxon tests were used.<h4>Results</h4>We screened 1658 NSCLC patients and identified 80 eligible subjects. The majority of patients had metastatic (<i>n</i> = 50, 63%) vs. localized (<i>n</i> = 30, 37%) NSCLC. Most patients de"],"journal":["Cancers"],"pagination":["2819"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12427550"],"repository":["biostudies-literature"],"pubmed_title":["Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study."],"pmcid":["PMC12427550"],"pubmed_authors":["Lee SM","Swanton C","Papadatos-Pastos D","Spicer J","Ahmad T","Forster M","Skwarski M","Georgiou A","Ghosh S","Gennatas S","Chitnis M","Karapanagiotou E","Jamal-Hanjani M","Josephides E","Coupe N","Benafif S","Mahmood U"],"additional_accession":[]},"is_claimable":false,"name":"Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.","description":"<h4>Purpose</h4>Evaluation of predictors and outcomes in NSCLC patients treated with an immune checkpoint inhibitor (ICI) following a severe immune-related adverse event (irAE).<h4>Methods</h4>We included all NSCLC patients receiving ≥1 ICI cycle and corticosteroids for CTCAE Grade ≥3 irAEs between 2017 and 2023 from three UK NHS teaching hospitals. Progression-free survival (PFS) and overall survival (OS) after the 1st irAE, best overall response (BOR) to ICI, and predictors of clinical benefit were evaluated. Kaplan-Meier, Cox and logistic regression models, and Wilcoxon tests were used.<h4>Results</h4>We screened 1658 NSCLC patients and identified 80 eligible subjects. The majority of patients had metastatic (<i>n</i> = 50, 63%) vs. localized (<i>n</i> = 30, 37%) NSCLC. Most patients de","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-15T03:18:28.597Z","creation":"2026-04-15T03:09:47.55Z"},"accession":"S-EPMC12427550","cross_references":{"pubmed":["40940918"],"doi":["10.3390/cancers17172819"]}}